EA033057B1 - Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека - Google Patents

Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека

Info

Publication number
EA033057B1
EA033057B1 EA201890361A EA201890361A EA033057B1 EA 033057 B1 EA033057 B1 EA 033057B1 EA 201890361 A EA201890361 A EA 201890361A EA 201890361 A EA201890361 A EA 201890361A EA 033057 B1 EA033057 B1 EA 033057B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
alkoxy
ris
compounds
tetrahydroisoquinolin
Prior art date
Application number
EA201890361A
Other languages
English (en)
Russian (ru)
Other versions
EA201890361A1 (ru
Inventor
Кайл Дж. Истман
Джон Ф. Кадоу
Кайли И. Парселла
Б. Нарасимхулу Наиду
Тао Ван
Чживэй Инь
Чжонсин Чзан
Original Assignee
ВАЙВ ХЕЛТКЕР ЮКей (№ 5) ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033057(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ВАЙВ ХЕЛТКЕР ЮКей (№ 5) ЛИМИТЕД filed Critical ВАЙВ ХЕЛТКЕР ЮКей (№ 5) ЛИМИТЕД
Publication of EA201890361A1 publication Critical patent/EA201890361A1/ru
Publication of EA033057B1 publication Critical patent/EA033057B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201890361A 2015-08-11 2016-08-10 Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека EA033057B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11
PCT/IB2016/054832 WO2017025917A1 (en) 2015-08-11 2016-08-10 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
EA201890361A1 EA201890361A1 (ru) 2018-11-30
EA033057B1 true EA033057B1 (ru) 2019-08-30

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890361A EA033057B1 (ru) 2015-08-11 2016-08-10 Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека

Country Status (23)

Country Link
US (2) US10189816B2 (enExample)
EP (1) EP3334716A1 (enExample)
JP (1) JP6782766B2 (enExample)
KR (1) KR20180032649A (enExample)
CN (1) CN108137534A (enExample)
AR (1) AR105653A1 (enExample)
AU (1) AU2016306089B2 (enExample)
CA (1) CA2994791A1 (enExample)
CL (1) CL2018000363A1 (enExample)
CO (1) CO2018001359A2 (enExample)
CR (1) CR20180091A (enExample)
DO (1) DOP2018000035A (enExample)
EA (1) EA033057B1 (enExample)
HK (1) HK1249503A1 (enExample)
IL (1) IL257240B (enExample)
MA (1) MA42614A (enExample)
MX (1) MX2018001722A (enExample)
PE (1) PE20181002A1 (enExample)
PH (1) PH12018500294A1 (enExample)
TW (1) TWI657086B (enExample)
UA (1) UA120464C2 (enExample)
WO (1) WO2017025917A1 (enExample)
ZA (1) ZA201800689B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180032650A (ko) * 2015-08-12 2018-03-30 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 5-(n-[6,5]-융합된 바이사이클릭 아릴 테트라하이드로이소퀴놀린-6-일) 피리딘-3-일 아세트산 유도체
TW201718537A (zh) * 2015-08-12 2017-06-01 Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物
WO2017195113A1 (en) * 2016-05-11 2017-11-16 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455214A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20200325127A1 (en) * 2016-05-11 2020-10-15 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565809A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2020503352A (ja) * 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130034A1 (en) * 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2015127003A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126726A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
RU2503679C2 (ru) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8377960B2 (en) * 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
ES2475970T3 (es) 2009-12-23 2014-07-11 Katholieke Universiteit Leuven Novedosos compuestos antivirales
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014164467A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
TW201718537A (zh) * 2015-08-12 2017-06-01 Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物
CN108137552A (zh) * 2015-08-12 2018-06-08 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的5-(n-稠合三环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
KR20180032650A (ko) * 2015-08-12 2018-03-30 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 5-(n-[6,5]-융합된 바이사이클릭 아릴 테트라하이드로이소퀴놀린-6-일) 피리딘-3-일 아세트산 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130034A1 (en) * 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2015127003A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126726A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERTO DI SANTO: "Inhibiting the HIV Integration Process: Past, Present, and the Future", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 57, no. 3, 13 February 2014 (2014-02-13), pages 539 - 566, XP055207945, ISSN: 00222623, DOI: 10.1021/jm400674a *

Also Published As

Publication number Publication date
MX2018001722A (es) 2018-05-16
EP3334716A1 (en) 2018-06-20
PH12018500294A1 (en) 2018-08-13
AU2016306089B2 (en) 2018-08-09
MA42614A (fr) 2021-05-26
CL2018000363A1 (es) 2018-07-06
US20190092754A1 (en) 2019-03-28
US20180230129A1 (en) 2018-08-16
KR20180032649A (ko) 2018-03-30
EA201890361A1 (ru) 2018-11-30
AR105653A1 (es) 2017-10-25
DOP2018000035A (es) 2018-03-30
ZA201800689B (en) 2021-08-25
IL257240B (en) 2020-02-27
CA2994791A1 (en) 2017-02-16
WO2017025917A1 (en) 2017-02-16
AU2016306089A1 (en) 2018-03-01
HK1249503A1 (zh) 2018-11-02
PE20181002A1 (es) 2018-06-26
IL257240A (en) 2018-03-29
TW201718549A (zh) 2017-06-01
US10189816B2 (en) 2019-01-29
CO2018001359A2 (es) 2018-05-10
CR20180091A (es) 2018-06-13
UA120464C2 (uk) 2019-12-10
JP6782766B2 (ja) 2020-11-11
TWI657086B (zh) 2019-04-21
JP2018522927A (ja) 2018-08-16
CN108137534A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
EA033057B1 (ru) Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
TN2017000535A1 (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
PH12012500752A1 (en) Benzimidazole-imidazole derivatives
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
PH12016500723A1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP4286372A3 (en) Pyrimidinones as factor xia inhibitors
MY174042A (en) Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX353412B (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX366123B (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
GEP20166484B (en) Protein kinase inhibitors
MX366787B (es) Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
JP2017526748A5 (enExample)
AU2012360910A8 (en) Quinazolinone derivatives as HCV inhibitors
MY203207A (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
WO2015198263A3 (en) Novel betulinic proline substituted derivatives as hiv inhibitors
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU